Trump’s Second Administration: Impact on the Pharmaceutical Industry
The second Trump administration has been in office for just over one year, but the whirlwind of activity across all areas of the government has created a constant stream of discussion and implementation of policy changes.
Meanwhile, the pharmaceutical industry has maintained strong growth over the past few years, fueled by technological innovation, an aging population, and strategic investments. Our prior blog series “Cancer Drugs: Antibody Drug Conjugates (ADCs) Keep Growing” highlighted some of these technological innovations and analyzed legal issues associated with these advancements. Our “AI in Health Care Series” discussed advances in AI and biotech, as well as legal questions that surround these remarkable developments.
In this new series, we will focus on recent developments under the current Trump administration and their impact on the pharmaceutical industry. These topics include:
- Increased oversight from State Attorney General’s Offices as many of the federal agencies reduce their headcount.
- Data privacy concerns relevant to the pharmaceutical industry.
- Pricing pressures in the life sciences and pharmaceutical industry.
- Branding issues unique to companies selling and marketing pharmaceuticals.
In addition, we will continue to provide updates on corporate, regulatory, and intellectual property legal issues of interest to the industry.
For additional resources on the Trump Administration’s impact on the pharmaceutical industry, visit Foley’s Trump Administration Resource Hub.
Foley is here to help you address the short- and long-term impacts in the wake of regulatory changes. We have the resources to help you navigate these and other important legal considerations related to business operations and industry-specific issues. Please reach out to the authors, your Foley relationship partner, our Health Care & Life Sciences Sector, or to our Innovative Technology Sector with any questions.
